PEDIATRIC PULMONOLOGY, cilt.50, sa.10, ss.1025-1032, 2015 (SCI-Expanded)
Background: Palivizumab prophylaxis for RSV has been consistently reported to reduce the risk of hospital admissions related to RSV infection in children with symptomatic cardiac disease. This study was designed to investigate the efficacy of palivizumab prophylaxis among infants with congenital heart disease (CHD) in Turkey.